Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target
I'm PortAI, I can summarize articles.
Analyst Justin Walsh from JonesTrading has reiterated a Buy rating on Perspective Therapeutics, maintaining a price target of $18. He believes the current share price does not reflect the company's advancing clinical pipeline, particularly the Pb-212-VMT-α-NET program. Walsh highlights the company's strong cash position and strategic investments in radiopharmaceutical manufacturing, which could enhance its appeal as an acquisition target. Upcoming clinical readouts in 2026 may serve as catalysts for growth. Wedbush also maintains a Buy rating with a $11 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments